Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Monzr M. Al Malki, Kaitlyn London, Janna Baez, Yu Akahoshi, William J. Hogan, Aaron Etra, Hannah Choe, Elizabeth O. Hexner, Amelia Langston, Sunil Abhyankar, Doris M. Ponce, Zachariah DeFilipp, Carrie L. Kitko, Kehinde Adekola, Ran Reshef, Francis Ayuk, Alexandra Capellini, Chantiya Chanswangphuwana, Matthias Eder, Gilbert Eng, Isha Gandhi, Stephan A. Grupp, Sigrun Gleich, Ernst Holler, Nóra Rebeka Jávorniczky, Stelios Kasikis, Steven Kowalyk, George Morales, Umut Özbek, Wolf Rösler, Nikolaos Spyrou, Gregory A. Yanik, Rachel Young, Yi‐Bin Chen, Ryotaro Nakamura, James L.M. Ferrara, John E. Levine
Abstract
Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is the main cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at onset of GVHD quantify GI crypt damage; AA2/3 scores correlate with resistance to treatment and higher NRM. We conducted a multicenter, phase 2 study using natalizumab, a humanized monoclonal antibody that blocks T-cell trafficking to the GI tract through the α4 subunit of α4β7 integrin, combined with corticosteroids as primary treatment for patients with new onset AA2/3 GVHD. Seventy-five patients who were evaluable were enrolled and treated; 81% received natalizumab within 2 days of starting corticosteroids. Therapy was well tolerated with no treatment emergent adverse events in >10% of patients. Outcomes for patients treated with natalizumab plus corticosteroids were compared with 150 well-matched controls from the MAGIC database whose primary treatment was corticosteroids alone. There were no significant differences in overall or complete response between patients treated with natalizumab plus corticosteroids and those treated with corticosteroids alone (60% vs 58%; P = .67% and 48% vs 48%; P = 1.0, respectively) including relevant subgroups. There were also no significant differences in NRM or overall survival at 12 months in patients treated with natalizumab plus corticosteroids compared with controls treated with corticosteroids alone (38% vs 39%; P = .80% and 46% vs 54%; P = .48, respectively). In this multicenter biomarker-based phase 2 study, natalizumab combined with corticosteroids failed to improve outcome of patients with newly diagnosed high-risk GVHD. This trial was registered at www.clinicaltrials.gov as # NCT02133924.